The choroid plexus consists of highly differentiated epithelium and functions as a barrier at the interface of the blood-cerebrospinal-fluid (CSF). This tissue may therefore determine the bioavailability and transport of drugs to the brain. Little is known about the expression of drug and xenobiotic metabolizing enzymes (DME) and of drug transporters in the human choroid plexus. Notably, the transcription factor and zinc finger protein HNF4alpha is a master regulator of DMEs and of drug transporters. As of today its activity in the blood-CSF barrier is unknown. Here we report our efforts in determining HNF4alpha activity in the regulation of ABC transporters in the human and rat choroid plexus.
Background
Drug delivery to the brain is mediated by several factors, most notably transport across the blood brain (BB) and the choroid plexus barrier; the latter displays drug-metabolizing enzyme and drug transport activity. It may therefore determine the overall cerebral bioavailability of drugs [1] . Specifically, the choroid plexus is located within brain vesicles. It is composed of a tight monolayer of polarized epithelial cells and forms the blood-cerebrospinal-fluid (CSF) barrier. Together with the blood-brain barrier, formed by endothelial cells of brain capillaries, it functions as the main interface between the central nervous system (CNS) and the peripheral circulation. Within the CNS this tissue is of great pharmacological interest, but information on the expression of efflux transporters such as the ATP binding cassette (ABC) proteins is missing [2] . In contrast, their expression in liver, kidney, and intestine has been studied in considerable detail [3] [4] [5] . Indeed, the ABC drug transporters extrude a variety of structurally diverse drugs, drug conjugates and metabolites in an active, ATP-dependent manner and even against high concentration gradients. The three main ABC families considered to be involved in the disposition of xenobiotics include the ABCB family (MDR subfamily, multidrug resistance, e.g. ABCB1/MDR1), the ABCC family of multidrug resistance proteins (MRP subfamily, multidrug resistance related proteins, e.g. ABCC2/MRP2), and the breast cancer resistance protein (ABCG2/BCRP) of the ABCG family [3, 4] . However, comprehensive studies on the expression levels of ATP transporters in the human choroid plexus have not been attempted.
Notably, there is clear evidence for HNF4a to play a role in the transcriptional control of drug transporters. Specifically, HNF4a is a member of the nuclear receptor superfamily and one of the key players in liver biology [6] [7] [8] . Among the genes regulated by HNF4a are a broad range of xenobiotic-metabolizing cytochrome P450 isozymes [9, 10] , UDP-glucuronosyltransferases [11] , sulfotransferases [12] and transporters including organic anion transporter 2 [13] , organic cation transporter 1 [14] , the ABC transporter ABCC2 [15] , ABCC6 [16] , ABCG5 [17] and ABCG8 [17] . Although there is clear evidence for HNF4a to be of key importance in the control of drug metabolism it may also play a role in the regulation of transporters in the choroid plexus. Here we report our efforts in mapping HNF4a to human and rat choroid plexus. We determined HNF4a DNA binding activity and searched for transcript expression of various ABCB and ABCC transporters in the human choroid plexus. Apart from qRT-PCR and immunohistochemistry studies we evidence ABCC1 gene expression to be highly dependent on HNF4a as determined in functional knock down studies. Overall, we provide evidence for HNF4a to be an important regulator of ABC drug transporters in the choroid plexus and thus may impact efficacy of pharmacotherapy targeted to the brain.
Results
Initially, we searched for HNF4a transcripts in individual samples of human and rat choroid plexus and confirmed gene expression of HNF4a by quantitative real time RT-PCR (Figures 1A) . We found HNF4a transcript expression in human and rat choroid plexus to account for approximately a tenth of its expression in the liver (Figures 1A) . It is of considerable importance that HNF4a expression in the human and rat choroid plexus is restricted to P1 promoter driven isoforms (Table 1 ). Furthermore, we studied expression of the insulin-like growth factor 2 (IGF2), tran-sthyretin (TTR) and the transcription factor FOXJ1 to further qualify choroidal epithelial cells of the brain [18, 19] . These transcripts are specifically enriched in choroid plexus. We observed abundant expression of IGF2, TTR and FOXJ1 in human choroid plexus as compared to total brain RNA extracts ( Figures 1B) . There is the need to study histological well qualified tissue, as studies with total brain RNA extracts would render findings meaningless as will be discussed later on. Unfortunately, sufficient human choroid plexus tissue suitable for the harvest of nuclear protein and to perform western blotting as well as EMSA assay could not be obtained. We nonetheless demonstrate HNF4a protein expression by immunohistochemistry by use of a specific HNF4a antibody for human (Figures 2A) and rat choroid plexus (Figures 2C). To confirm specificity an excess of antigen preabsorbed to the antibody was used (Figures 2B, D).
We then analyzed expression of different members of the ABCB (MDR subfamily, multidrug resistance)/ABCC (MRP subfamily, multidrug resistance related) gene families in the human choroid plexus by quantitative real time RT-PCR and report results for n = 3 individual human choroid plexus samples. mRNA expression of ABCB4 (MDR2/3), ABCC1 (MRP1), ABCC2 (MRP2), ABCC3 (MRP3), ABCC4 (MRP4), ABCC5 (MRP5) and ABCC6 (MRP6) was comparable to its expression level in commercially available control total human brain RNA extracts (Figures 1C). mRNA expression of ABCB1 (MDR1) determined in choroidal epithelium was lower than in human liver (n = 4) and in brain (Figures 1C).
We then searched for HNF4a binding sites in proximal promoter sequences (up to -7000 bp) of drug transporter coding genes. For this purpose, we used two different bioinformatic approaches (see Material and Methods section HNF4aP1 and P2 gene expression was measured in human and rat choroid plexus (n = 3, respectively) by real-time quantitative RT-PCR and computed relative to expression of mitATPase6, which served as a housekeeping gene. Patient characteristics are given in Table 5 . Caco-2 cells and pancreatic tissue served as controls for HNF4aP2 expression in human and rats, respectively.
for a description of the employed algorithms). We observed three binding sites within the ABCB4 promoter, spaced approximately by 600 bp and 1600 bp and two recognition sites within the ABCC1 promoter ( Table 2) . Predicted binding sites were confirmed by EMSA band shift assays. We used 32 P-labeled double-stranded DNA probes to specifically probe for HNF4a-sites located in the human ABCB4 (hABCB4_1, hABCB4_2 and hABCB4_3) and in the human ABCC1 (hABCC1_1, hABCC1_2) gene. Note, DNA binding of nuclear extracts to the A-site of the HNF1a-promoter (HNF1pro) served as a positive control.
This site is an established recognition site for HNF4a. Unfortunately, sufficient amount of human choroid plexus suitable for the isolation of nuclear protein could not be obtained. Instead, we used nuclear extracts isolated from the human intestinal cell line Caco-2 which expresses several ABC transporter genes [20] and therefore is a rich source of HNF4a nuclear protein. Indeed, HNF4a protein expression in Caco-2 cells is comparable to organs such as the liver [21] . As depicted in Figures 3A we observed strong binding of HNF4a to the A-site of the HNF1a-promoter. We also observed strong binding of Gene expression of HNF4a and different ABC transporters in the choroid plexus HNF4a to the predicted sites in the promoters of ABCB4 and ABCC1 (Figures 3A) ; bands could be shifted with a specific HNF4a antibody therefore demonstrating selectivity and specificity of the assay. Alignment of human, rat and mouse ABCB4 and ABCC1 genes did not identify common HNF4alpha binding sites. This points to differences in the molecular organization of ABC promoters in orthologous genes. HNF4alpha binding sites for the rat and mouse ABCB4 and ABCC1 genes are given in Table 2 ,
whereas the sequences of oligonucleotides to confirm the predicted sites experimentally are shown in Table 3 . As shown in Figures 3B and 3C EMSA band shift assays confirmed binding of HNF4a to rat and mouse ABCB4 and ABCC1 targeted sequences.
To further probe for the role of HNF4a in ABC gene regulation we employed an siRNA approach. Specifically, siRNA-mediated functional knock down of HNF4a in the Immunohistochemical detection of HNF4a in the choroid plexus . To confirm specificity of the immunohistochemical localization antibodies were preabsorbed with excess of antigens for HNF4a (B, D). Patient identification numbers were indicated respectively and patient characteristics are given in Table 5 . Magnification ×400.
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human Caco-2 cell line resulted in significantly decreased gene expression of ABCC1 (Table 4 ; for transfection efficiency and stable expression of mitATPase6 after transfection see Niehof and Borlak, 2008 [22] ). These results confirm ABCC1 to be a gene target of HNF4a. ABCB4 expression in Caco-2 cells is near the limit of detection.
Consequently, knockdown experiments are not meaningful.
Discussion
Our study aimed for a better understanding of the role of HNF4a in the regulation of drug transporters. Here we present evidence for expression of HNF4a in the epithelium of the CSF barrier. By applying position weight matrices to genomic sequences of ABC transporters we were able to predict HNF4a binding sites in the promoters of the ABCB4 and ABCC1 gene. The predicted binding sites were then confirmed by EMSA band shift assays. We propose a role for HNF4a in the regulation of drug trans- Transfac matrix (V$HNF4_01) or self-generated matrix (V$zemlin13_11045) with a setting of core and matrix similarity 0.9 was used. 
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The central five nucleotides of the HNF4a binding site are highlighted in bold letters. The two direct repeats (DR1) separated by a spacer of one nucleotide are underlined.
HNF4a binding to promoters of ABCB4 and ABCC1 Figure 3 HNF4a binding to promoters of ABCB4 and ABCC1. Electrophoretic mobility shift assays with 2,5 mg Caco-2 cell nuclear extract and oligonucleotides corresponding to the A-site of the HNF1a promoter (HNF1pro) and to putative HNF4a binding-sites within human (A), rat (B) and mouse (C) ABCB4 and ABCC1 as 32 P labeled probe. In supershift assays an antibody directed against HNF4a (+) was added. For oligonucleotide sequence information see Table 2 and 3. Functional knock down of HNF4a was already reported [22] . * A student's t test was done to compare HNF4a siRNA transfection against negative siRNA transfected controls. The results were considered significant when the p value was less than 0.05. Gene expression was determined by realtime quantitaive RT-PCR in triplicates; mitATPase6 served as housekeeping gene. The DDC T -method was used to determine repression of gene expression. Values for HNF4a siRNA transfection represent transcript abundance relative to negative siRNA transfected controls, which were set to 100%.
porters of the choroid plexus. Notably, HNF4a is a key player in the regulation of genes coding for various metabolic pathways and of xenobiotic metabolism [6] [7] [8] [9] 23, 24] . This protein also promotes expression of an epithelial phenotype [25] [26] [27] . Specifically, epithelium of the choroid plexus cells is highly differentiated and functions as a blood-CSF barrier. The expression of HNF4a in the epithelium of the choroid plexus and its DNA binding to regulatory sequences of drug transporters is a novel finding. Its expression accounts for approximately a tenth of HNF4a expression found in liver. Furthermore, there is evidence for HNF4a to undergo alternative splicing with isoforms may arising from alternative splicing and/or usage of two different promoters [6] . Specifically, the P1 promoter generates six different isoforms (HNF4a1-a6); but activation of the P2 promoter results in isoforms HNF4a7-a9. P2 promoter-driven HNF4a isoforms are expressed throughout mouse liver development, but dis-appear after birth, while P1 promoter-driven transcripts are abundantly expressed postnataly [28] . Additionally, P2 isoforms are induced in mouse and human hepatocellular carcinoma [29, 30] and are primarily expressed in human pancreatic islets and exocrine cells [31] . In the case of the choroid plexus it appears that expression of HNF4a is restricted to P1 promoter-driven isoforms. HNF4a protein expression in human and rat choroid plexus could be clearly evidenced by immunohistochemistry. To further qualify tissue preparations of choroid plexus expression of IGF2, TTR and FOXJ1 was investigated; their expression are accepted genetic markers of the choroid plexus [18, 19] . We validated tissue preparations by morphological and genetic markers. Unlike previous studies where expression of HNF4a transcripts could not be evidenced in total RNA extracts of the brain [6] , we were able to confirm expression of HNF4a in the choroid plexus of human and rat brain. Most certainly, total brain RNA extracts dilute copy number of HNF4a transcripts to presumable levels below the limit of detection. Here, we evidence binding of HNF4a to regulatory sequences of drug transporters expressed in the choroid plexus and analyzed gene expression of ABC transporters in patients with different causes of death, but the functional significance of the newly identified HNF4a binding sites in activating the ABCB4 and ABCC1 promoters still needs to be established.
In the past attempts to detect HNF4a DNA binding in a choroid plexus papilloma failed [32] . The investigators performed EMSA experiments with nuclear extracts of rat liver, kidney and intestine and of SV40-induced choroid plexus papilloma of transgenic mice, but unfortunately probed for HNF4alpha binding with an oligonucleotide corresponding to the HNF4a binding site in the mouse TTR (transthyretin) promoter. The authors did not employ an antibody in EMSA band shift assays; instead, competition with excess of unlabeled probes was done. Although the authors described a weak binding of HNF4a with nuclear extracts from kidney they considered intestine as well as choroid plexus as deficient for HNF4a binding. There is a need to consider tissue specific DNA binding activity. HNF4a binding at the TTR promoter is much less as compared to the A-site in the HNF1 promoter (not exceeding a tenth, data not shown). As detailed above, HNF4a gene expression in human and rat choroid plexus is approximately one tenth of its expression in the liver (see Figures 1A) . It is therefore not surprising that previous investigators [32] failed to detect HNF4a protein in intestine and choroid plexus, even though the authors described weak expression of this protein in kidney. By now, it is well established that HNF4a expression is not restricted to liver, but also functions in kidney and intestine [33, 34] . Here we evidence by immunohistochemical staining HNF4a to be expressed in epithelium of human and rat choroid plexus (see Figures 2) .
Notably, the choroid plexus functions as a barrier for drug uptake to the brain. This tissue expresses drug metabolizing enzymes (DMEs) and some transporters [1] . Expression of DMEs in the choroid plexus is part of a defense program to prevent entry of xenobiotics into the brain. The blood-CSF barrier also regulates entry and distribution of various pharmacologically active compounds between the blood and the CSF interface and is basically involved in numerous exchange processes thereby determining the supply of the brain with nutrients and hormones [1] . Indeed, endogenous metabolites, as well as neurotransmitter and metabolites from the brain are cleared via this barrier [19] . In drug therapies efflux transporters of the ABC-family are of pivotal importance in determining therapeutic tissue levels. In the past research focused on their regulation in liver, kidney and intestine [3, 4] . The knowledge on drug transporter in specialized tissues of the brain is incomplete. Specifically, ABCB (MDR) proteins accept a broad range of substrates and may transport large lipophilic, neutral or cationic compounds. This includes a vast number of neuropharmacological drugs such as antiepileptic and antiviral drugs, antidepressants, opiods, antipsychotics and tranquilizer [35] [36] [37] [38] [39] [40] . ABCB1, a transporter with highest expression in the gastrointestinal tract [4, 41] , is expressed at low levels in human choroid plexus, that is much lower than in liver and total brain. Our findings are consistent with results reported previously for rats [42] . Its apical expression in rat, mouse and human choroidal epithelium was shown previously [43] . Furthermore, ABCB4 is highly expressed in the liver, where it is acting as a "flippase" in transporting phospholipids into the bile, but ABCB4 can also bind and transport a subset of ABCB1 substrates with an overlap in substrate specificity [44] . As reported for ABCB1, ABCB4 is expressed at low levels in human choroid plexus, i.e. more than 500 fold lower than in liver. Low ABCB4 expression was also evidenced in choroidal epithelium of the rat [42] , but to the best of our knowledge our study is the first report on expression in human choroid plexus. An apical distribution of ABCB1 in neonatal cultured rat choroid plexus cells imply a drug transport from blood into CSF [43] . In endothelial cells of small blood capillaries of the blood-brain barrier, apical located ABCB1 pumps drugs back into the blood stream and therefore limits drug penetration to the brain [2] .
Likewise, the ABCC (MRP) proteins are multispecific organic anion transporters and accept glucurono-, glutathione-and sulfo-conjugates. They transport physiological substrate conjugates as well as drug conjugates. Expression of ABCC1-6 mRNA transcripts was reported for rat choroid plexus [42] as was expression of ABCC1 for human choroid plexus [43, 45, 46] . ABCC1, ABCC4 and ABCC5 were expressed in human choroid plexus at least at 10 fold higher than in liver; whereas ABCC2, ABCC3 and ABCC6 were expressed up to 800 fold lower than liver. Similar results were reported for ABCC transporter expression in rat choroid plexus [42] . Notably, ABCC1 is localized at the basolateral membrane of choroid plexus [43, 45, 46] , but Gazzin et al [46] described a major difference in the localization of ABCB1 and ABCC1 proteins between the blood-brain and the blood-CSF barrier with strongest expression of ABCC1 at the choroidal epithelium. Indeed, ABCC proteins contribute to the protective role of the choroid plexus and mediate basolateral efflux of conjugates resulting from choroidal drug metabolism into the blood. Although it is known that the choroid plexus is important in regulating the distribution of various pharmacologically active compounds between the blood and the CSF, the characterization of the involved human ABC transporters gives new insights into the function of the CSF barrier. Furthermore, ABCBs (MDRs) and ABCCs (MRPs) are inducible transporters and are highly responsive to chemotherapeutics, carcinogens, inflammation, heat shock, hypoxia and irradiation [47] . They are regulated by a complex network of transcriptional cascades, such as by multiple ligand activated nuclear receptors like retinoid X receptor (RXR), farnesoid X receptor (FXR), constitutive androstane receptor (CAR) and the xenobiotic receptor pregnane X receptor (PXR) [47, 48] . There is also evidence for the transcription factors AP-1, p53, Egr-1 and WT-1 to participate in their regulation with NF-Y, Sp1 and Sp3 being involved in the constitutive expression [47] .
Recently, an upregulation of ABCB1, ABCB4 and ABCC4 transcripts was reported in human embryonic kidney cells that conditionally expressed wild-type HNF4a [33] . An important role of HNF4a in the transcriptional control of drug transporters was reported for human hepatocytes as determined by adenoviral HNF4a-siRNA mediated knockdown [49] . We also employed an siRNA mediated functional knockdown of HNF4a and found ABCC1 gene expression to be massively repressed. There is a need to improve an understanding of the mechanism by which transporters are regulated. This will impact the design of novel CNS therapeutics. Targeting transporters may thus be useful in achieving therapeutic tissue levels of CNS drugs.
Conclusion
We report expression of HNF4a in choroid plexus of the human and rat brain. This factor might regulate expression of some ATP binding cassette transporters. Targeting of HNF4a may impact efficacy of pharmacotherapy of CNS drugs.
Methods
Human and rat tissue
A total of n = 7 human and n = 7 rat tissues were analyzed. Samples of human choroid plexus (n = 3, gene expression analysis) were kindly provided by T. Arendt (Department of Neuroanatomy, Paul-Flechsig-Institute, University of Leipzig, Germany). Paraffin-embedded slices of human choroid plexus for immunohistochemistry (n = 4) were kindly provided by C. Grothe (Institute of Neuroanatomy, Hannover Medical School, Hannover, Germany). Human liver tissue (gene expression analysis) was obtained from patients undergoing hepatic resections and were kindly provided by J. Klempnauer (Department of Visceral and Transplantation Surgery, Hannover Medical School, Hannover, Germany). Patient characteristics are given in Table  5 . Control human brain RNA was purchased from BD Biosciences (Heidelberg, Germany).
Samples of rat choroid plexus (n = 3, Sprague Dawley rats, gene expression analysis) were kindly provided by H. Hilbig and K. Spanel-Borowski (Department of Anatomy, University of Leipzig, Germany). Samples of rat liver and brain (Sprague Dawley rats, gene expression analysis) were generated in-house. Paraffin-embedded slices of rat brain (Sprague Dawley rats) containing choroid plexus regions for immunohistochemistry (n = 4) were kindly provided by C. Grothe (Institute of Neuroanatomy, Hannover Medical School, Hannover, Germany).
Quantitative real-time RT-PCR
Analysis of human samples: Three human choroid plexus samples and four human liver samples were analyzed separately and used for calculation of the mean and standard deviation. Analysis of rat samples: Three rat choroid plexus samples, three rat liver and three rat brain samples were analyzed separately and used for calculation of the mean and standard deviation. Total RNA from choroid plexus and liver was isolated using the RNeasy Mini Kit (Qiagen, Hilden, Germany) according to the manufacturers recommendations. Subsequently to RNA isolation, a DNase I digest was performed. 4 mg total RNA from each sample was used for reverse transcription (Omniscript Reverse Transcriptase, Qiagen, Hilden, Germany). Quantitative real-time RT-PCR measurement was done with the Lightcycler (Roche Diagnostics, Mannheim, Germany) with the following conditions: denaturation at 95°C, annealing at different temperatures for 8 sec, extension at 72°C for different times and detection of SYBR-Green Ifluorescence at different temperatures. Detailed primer specific conditions and oligonucleotide sequence information are given in Table 6 . Relative quantification was performed using the "Fit Points Method" of the LightCycler3 Data Analysis Software version 3.5.28 (Roche Diagnostics, Mannheim, Germany) by comparing the sample values to a standard curve within the linear range of amplification. This comparison was performed during each LightCycler Run (for genes of interest as well as for the housekeeping gene, i.e. mitATPase6). The standardized sample values for each gene of interest were divided by the standardized values of the housekeeping gene. The slope of external standard curves are given in Table 6 , indicating the PCR efficiency for each amplicon.
Caco-2 cell culture
Caco-2 cells are a valuable source for HNF4a nuclear protein [21] and were obtained from and cultivated as recommended by DSMZ (Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH, Braunschweig, Germany) and seeded with a density of 4 × 10 6 cells per 75 cm 2 flask and harvested after 11 days of culture.
Isolation of nuclear extracts
Nuclear extracts from Caco-2 cells were isolated by the modified method of Dignam et al [50] . Eleven days after seeding cells were washed twice with ice-cold PBS, scraped into microcentrifuge tubes and centrifuged for 5 min at 2000 × g, 4°C. Cell pellets were resuspended in lysis buffer (10 mM Tris pH 7.4, 2 mM MgCl 2 , 140 mM NaCl, 1 mM DTT, 4 mM Pefabloc, 1% Aprotinin, 40 mM b-glycerophosphate, 1 mM sodiumorthovanadate and 0.5% TX100) at 4°C for 10 min (300 ml for 1 × 10 7 cells), transferred onto one volume of 50% sucrose in lysis buffer and centrifuged at 14000 × g and 4°C for 10 min. Nuclei were resuspended in Dignam C buffer (20 mM Hepes pH 7.9, 25% glycerol, 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 1 mM DTT, 4 mM Pefabloc, 1% Aprotinin, 40 mM b-glycerophosphate, 1 mM sodiumorthovanadate, 30 ml for 1 × 10 7 cells) and gently shaked at 4°C for 30 min. Nuclear debris was removed by centrifugation at 14000 × g at 4°C for 10 min. Protein concentrations were determined according to the method of Smith et al [51] . The extracts were aliquoted and stored at -70°C.
Electrophoretic mobility shift assays
Forward and reverse oligonucleotides (for sequence information see Table 3 ) were purchased from MWG Biotech (Ebersberg/Muenchen, Germany), annealed and 32 Plabeled using 32 Pg ATP and T4-kinase (New England Biolabs, Frankfurt, Germany). 2,5 mg Caco-2 cell nuclear extract and 10 5 cpm (0.027 ng) radiolabeled probe were incubated in binding buffer consisted of 25 mM HEPES, pH 7.6, 5 mM MgCl 2 , 34 mM KCl, 2 mM DTT, 2 mM Pefabloc, 2% Aprotinin, 40 ng of poly (dI-dC)/ml and 100 ng of bovine serum albumin/ml for 20 minutes on ice. Free DNA and DNA-protein complexes were resolved on a 6% polyacrylamide gel (acrylamide: bisacrylamide ratio = 37.5:1). Super shift experiments were done with a 1 mg HNF4a specific antibody (sc-6556x, Santa Cruz Biotechnology, Heidelberg, Germany). DNA binding of nuclear extracts to the A-site of the HNF1a-promoter (HNF1pro) served as a positive control.
Bioinformatic searches for HNF4a binding-sites
The transcription start site (TSS, +1) of the NCBI mRNA reference sequence (RefSeq) was aligned using the UCSC Genome Browser http://genome.ucsc.edu/ for promoter annotation of the respective genes. Proximal promoters (up to -7000 bp) of human ABCB1, ABCB4 and ABCC1 to ABCC6 were checked for putative HNF4a binding-sites with the tool MATCH [52] , http://www.biobase.de by employing two different weight matrix, i.e. V$HNF4_01, Transfac matrix (generated by Biobase) and V$zemlin13-11045 (self-generated). V$zemlin13-11045 is based on a collection of 33 well known HNF4a sites and was generated using the matrix generation tool of Biobase http:// www.biobase.de. At least one of both matrices has to exceed the cut-off of 0.9 for core similarity and 0.9 for matrix similarity (Table 2 ). Furthermore, proximal promoters (up to -7000 bp) of rat and mouse ABCB4 and ABCC1 were checked for putative HNF4a binding sites ( Table 2) .
Immunohistochemistry
The sections were deparaffinized, demasked by heating, incubated with 0,6% H 2 O 2 in methanol for 30 min, and subsequently with protein block serum-free reagent (Dako, Glostrup, Denmark) for 10 min. Incubation with polyclonal antibody (Santa Cruz Biotechnology, Heidelberg, Germany) against HNF4a (sc-6556x, 1:400 dilution for rat sections, 1:200 dilution for human sections) was performed for 45 min. The sections were rinsed with Trisbuffered saline, incubated with biotinylated universal secondary antibodies (Dako, Glostrup, Denmark) for 15 min and subsequently with horseradish peroxidase-conjugated streptavidin solution (Dako, Glostrup, Denmark) for 15 min. Labeling was detected using a diaminobenzidine (DAB) chromogen solution (Dako, Glostrup, Denmark) for 5 min. The sections were counterstained with hematoxylin before examination under light microscope. To confirm the specificity of the immunohistochemical localization, antibodies preabsorbed 2 h with a twenty fold excess of antigen for HNF4a (sc-6556P, Santa Cruz Biotechnology, Heidelberg, Germany) were used.
siRNA silencing of HNF4a
Human HNF4a-specific siRNA probes were purchased from Qiagen (Hilden, Germany). Caco-2 cells (1,5 × 10 5 cells/well in 24-well plate) were transfected in triplicate for 48 h with 25 nM of the siRNA duplex using HiPerFect transfection reagent (Qiagen, Hilden, Germany). Alexa-Fluor488 labeld siRNA (Qiagen, Hilden Germany) was used as negative siRNA and as positive control for transfection efficiency. For transfection efficiency and stable expression of mitATPase6 after transfection see Niehof and Borlak, 2008 [22] .
